SCHEMBL5763662

SCHEMBL5763662

Cc1cc(C)c(-n2cnc3c(C(N)c4ccccc4)cc(C)nc32)c(C)c1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CRHR1 P34998 2/20 0.39
ALDH1A1 P00352 4/20 0.32
HPGD P15428 3/20 0.32
KDM4E B2RXH2 2/20 0.32
XDH P47989 2/20 0.32
MEN1 O00255 3/20 0.31
KMT2A Q03164 3/20 0.31
NPC1 O15118 2/20 0.31
RAB9A P51151 2/20 0.31
SMN1; SMN2 Q16637 2/20 0.31
MAPT P10636 2/20 0.31
PI4KA P42356 1/20 0.31
PI4K2B Q8TCG2 1/20 0.31
PI4K2A Q9BTU6 1/20 0.31
PI4KB Q9UBF8 1/20 0.31
TP53 P04637 1/20 0.31
ALOX15 P16050 1/20 0.31
TSHR P16473 1/20 0.31
MAPK1 P28482 1/20 0.31
GFER P55789 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5763890 0.80 DPP4 (0.38) CRHR1ALDH1A1HPGDKDM4EMEN1
SCHEMBL5762797 0.74 CRHR1 (0.46) CRHR1ALDH1A1HPGDKDM4EXDH
SCHEMBL5843198 0.67 CRHR1 (0.48) CRHR1
SCHEMBL5844074 0.67 CRHR1 (0.47) CRHR1
SCHEMBL5762166 0.64 CRHR1 (0.42) CRHR1
SCHEMBL14675573 0.63 TACR1 (0.41) ALDH1A1HPGDMEN1KMT2ASMN1; SMN2
SCHEMBL14677950 0.63 TACR1 (0.41) ALDH1A1HPGDMEN1KMT2ASMN1; SMN2
SCHEMBL14677066 0.63 TACR1 (0.41) ALDH1A1HPGDMEN1KMT2ASMN1; SMN2
Hydrochloric Acid SCHEMBL14676736 0.62 SLC6A2 (0.41) ALDH1A1HPGDMEN1KMT2ASMN1; SMN2
Hydrochloric Acid SCHEMBL14676739 0.62 SLC6A2 (0.41) ALDH1A1HPGDMEN1KMT2ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7074929-B2 Certain alkylene diamine-substituted heterocycles NEUROGEN CORP. (US) 2006-07-11 US disclosed
EP-1224187-B1 CERTAIN ALKYLENE DIAMINE-SUBSTITUTED HETEROCYCLES NEUROGEN CORP (US) 2006-02-22 EP disclosed
US-20040229870-A1 Certain alkylene diamine-substituted heterocycles NEUROGEN CORPORATION 2004-11-18 US disclosed
US-6696445-B2 NEUROPEPTIDE Y RECEPTOR ANTAGONISTS COMPRISING HETEROCYCLIC NITROGEN COMPOUNDS AND/OR PRODRUGS USED FOR PROPHYLAXIS OF EATING AND CARDIOVASCULAR DISORDERS NEUROGEN CORPORATION 2004-02-24 US disclosed
US-20030158197-A1 Certain alkylene diamine-substituted heterocycles NEUROGEN CORPORATION 2003-08-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030158197-A1 Certain alkylene diamine-substituted heterocycles NPY1R, NPY5R, NPY2R CRHR1 16/4885ALDH1A1 4696/4885HPGD 1838/4885
US-20040229870-A1 Certain alkylene diamine-substituted heterocycles NPY1R, NPY5R, NPY2R CRHR1 14/4885ALDH1A1 4696/4885HPGD 1846/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.